Novartis secures FDA RMAT designation for Kymriah to treat follicular lymphoma
Novartis has secured the US Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation, with an investigational new indication for Kymriah (tisagenlecleucel) to treat relapsed or